MBX Biosciences (MBX) News Today $10.88 -0.95 (-8.03%) Closing price 04:00 PM EasternExtended Trading$10.54 -0.34 (-3.13%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Acquires 47,502 Shares of StockMBX Biosciences, Inc. (NYSE:MBX - Get Free Report) Director Carl L. Gordon purchased 47,502 shares of the firm's stock in a transaction on Friday, February 14th. The stock was acquired at an average price of $9.87 per share, with a total value of $468,844.74. Following the completion of the transaction, the director now owns 3,205,930 shares in the company, valued at approximately $31,642,529.10. This trade represents a 1.50 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.February 20 at 8:19 PM | marketbeat.comMBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon Purchases 143,170 SharesMBX Biosciences, Inc. (NYSE:MBX - Get Free Report) Director Carl L. Gordon acquired 143,170 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was acquired at an average cost of $10.84 per share, for a total transaction of $1,551,962.80. Following the transaction, the director now directly owns 3,255,000 shares in the company, valued at $35,284,200. The trade was a 4.60 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.February 20 at 8:19 PM | marketbeat.comInsider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Buys 47,502 Shares of StockMBX Biosciences, Inc. (NYSE:MBX - Get Free Report) Director Carl L. Gordon purchased 47,502 shares of the stock in a transaction dated Friday, February 14th. The shares were acquired at an average price of $9.87 per share, with a total value of $468,844.74. Following the transaction, the director now owns 3,205,930 shares in the company, valued at $31,642,529.10. This trade represents a 1.50 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.February 20 at 5:10 AM | marketbeat.comMBX Biosciences to Participate in March Investor ConferencesFebruary 18 at 8:00 AM | globenewswire.comSmaller biotechs see new mechanisms of actions as future of obesity treatmentsFebruary 10, 2025 | msn.comStifel Nicolaus Reaffirms Their Buy Rating on MBX Biosciences, Inc. (MBX)February 10, 2025 | markets.businessinsider.comP. Kent Hawryluk Acquires 50,000 Shares of MBX Biosciences, Inc. (NYSE:MBX) StockMBX Biosciences, Inc. (NYSE:MBX - Get Free Report) CEO P. Kent Hawryluk acquired 50,000 shares of the company's stock in a transaction dated Tuesday, February 4th. The stock was acquired at an average cost of $10.69 per share, for a total transaction of $534,500.00. Following the completion of the purchase, the chief executive officer now directly owns 448,277 shares in the company, valued at $4,792,081.13. This trade represents a 12.55 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.February 5, 2025 | marketbeat.comMaze Therapeutics valued at $690.4 million in lukewarm Nasdaq debutJanuary 31, 2025 | msn.comMetsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debutJanuary 31, 2025 | msn.comWeight-loss drug developer Metsera raises $275 million in US IPOJanuary 31, 2025 | msn.comWeight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPOJanuary 27, 2025 | msn.comWeight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPOJanuary 27, 2025 | msn.comMBX Biosciences to Participate in Upcoming February Investor ConferencesJanuary 23, 2025 | finance.yahoo.comWeight-loss drug developer Metsera reveals wider loss in US IPO filingJanuary 11, 2025 | msn.comEarly success for MBX in Phase I trial of GLP-1RA for hypoglycaemiaJanuary 8, 2025 | msn.comMBX Biosciences announces phase 1 topline resuts for MBX 1416January 8, 2025 | markets.businessinsider.comMBX Biosciences (NYSE:MBX) Shares Gap Down - Time to Sell?MBX Biosciences (NYSE:MBX) Shares Gap Down - Should You Sell?January 7, 2025 | marketbeat.comMBX Biosciences' MBX 1416 Shows Positive Phase 1 Data In PBH; Stock Down In Pre-marketJanuary 7, 2025 | markets.businessinsider.comMBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric HypoglycemiaJanuary 7, 2025 | globenewswire.comMBX Biosciences (NYSE:MBX) Trading Down 6.6% - Here's WhyMBX Biosciences (NYSE:MBX) Stock Price Down 6.6% - Should You Sell?January 3, 2025 | marketbeat.comMBX Biosciences (NYSE:MBX) Shares Down 7.3% - Time to Sell?MBX Biosciences (NYSE:MBX) Shares Down 7.3% - Time to Sell?December 27, 2024 | marketbeat.comInvestors optimistic about continued biotech and medtech IPO resurgence in 2025December 23, 2024 | finance.yahoo.comFranklin Resources Inc. Invests $11.69 Million in MBX Biosciences, Inc. (NYSE:MBX)Franklin Resources Inc. bought a new stake in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 450,000 shares of the company's stock, valued at approxiDecember 22, 2024 | marketbeat.comMBX Biosciences (NYSE:MBX) Shares Gap Down - Should You Sell?MBX Biosciences (NYSE:MBX) Shares Gap Down - Here's WhyDecember 20, 2024 | marketbeat.comTeachers Retirement System of The State of Kentucky Purchases Shares of 26,708 MBX Biosciences, Inc. (NYSE:MBX)Teachers Retirement System of The State of Kentucky purchased a new position in MBX Biosciences, Inc. (NYSE:MBX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 26,708 shares of the compDecember 19, 2024 | marketbeat.comMBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2024 | finance.yahoo.comMBX Biosciences (NYSE:MBX) Trading 4.6% Higher - Here's WhyMBX Biosciences (NYSE:MBX) Stock Price Up 4.6% - Time to Buy?December 17, 2024 | marketbeat.comMBX Biosciences (NYSE:MBX) Shares Gap Up - Here's WhyMBX Biosciences (NYSE:MBX) Shares Gap Up - Still a Buy?December 16, 2024 | marketbeat.com46,194 Shares in MBX Biosciences, Inc. (NYSE:MBX) Purchased by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company acquired a new stake in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 46,194 shares of the company's stock,December 12, 2024 | marketbeat.comWellington Management Group LLP Buys Shares of 2,937,853 MBX Biosciences, Inc. (NYSE:MBX)Wellington Management Group LLP bought a new stake in MBX Biosciences, Inc. (NYSE:MBX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,937,853 shares of the companDecember 11, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Acquires Shares of 5,985,347 MBX Biosciences, Inc. (NYSE:MBX)Frazier Life Sciences Management L.P. bought a new stake in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 5,985,347 shares of the company's stock, valued at approximately $155,December 10, 2024 | marketbeat.comMBX Biosciences (NYSE:MBX) Shares Gap Down - What's Next?MBX Biosciences (NYSE:MBX) Shares Gap Down - Here's What HappenedDecember 6, 2024 | marketbeat.comRA Capital Management L.P. Makes New Investment in MBX Biosciences, Inc. (NYSE:MBX)RA Capital Management L.P. bought a new position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,511,334 shares of the comDecember 5, 2024 | marketbeat.comMaven Securities LTD Purchases Shares of 50,000 MBX Biosciences, Inc. (NYSE:MBX)Maven Securities LTD purchased a new stake in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 50,000 shares of the company's stock, valued at approximateDecember 5, 2024 | marketbeat.comMBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and MetabolismDecember 3, 2024 | markets.businessinsider.comMBX Biosciences announces publication of MBX 2109 Phase 1 study resultsDecember 3, 2024 | markets.businessinsider.comNEA Management Company LLC Makes New $93.90 Million Investment in MBX Biosciences, Inc. (NYSE:MBX)NEA Management Company LLC bought a new position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,614,486 shares of the company's stock, valuDecember 1, 2024 | marketbeat.comMBX Biosciences (NYSE:MBX) Shares Down 3.6% - Should You Sell?MBX Biosciences (NYSE:MBX) Stock Price Down 3.6% - Here's WhyNovember 29, 2024 | marketbeat.comBehind the Bell: MBX BiosciencesNovember 25, 2024 | nasdaq.comMBX Biosciences (NYSE:MBX) Shares Up 6.5% - Here's WhyMBX Biosciences (NYSE:MBX) Shares Up 6.5% - Should You Buy?November 22, 2024 | marketbeat.comMBX Biosciences completes phase 1 trial of diabetes drugNovember 20, 2024 | uk.investing.comMBX Biosciences (NYSE:MBX) Shares Gap Down - Here's What HappenedMBX Biosciences (NYSE:MBX) Shares Gap Down - Here's What HappenedNovember 19, 2024 | marketbeat.comMBX Biosciences completes last visit in Phase 1 MBX 1416 trial in hypoglycemiaNovember 19, 2024 | markets.businessinsider.comMBX Biosciences (NYSE:MBX) Shares Gap Up - Time to Buy?MBX Biosciences (NYSE:MBX) Shares Gap Up - Should You Buy?November 18, 2024 | marketbeat.comMBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric HypoglycemiaNovember 18, 2024 | globenewswire.comMBX Biosciences, Inc. (MBX)November 15, 2024 | finance.yahoo.comMBX Biosciences (NYSE:MBX) Sets New 1-Year Low - What's Next?MBX Biosciences (NYSE:MBX) Hits New 1-Year Low - Should You Sell?November 15, 2024 | marketbeat.comMBX Biosciences: Decent Potential For Lead Indication, But Need More DataNovember 14, 2024 | seekingalpha.comMBX Biosciences Reports Q3 2024 Financial ProgressNovember 9, 2024 | tipranks.comMBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 | finance.yahoo.com Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address MBX Media Mentions By Week MBX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBX News Sentiment▼1.620.60▲Average Medical News Sentiment MBX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBX Articles This Week▼63▲MBX Articles Average Week Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ardelyx News Today Indivior News Today Nurix Therapeutics News Today Vir Biotechnology News Today Syndax Pharmaceuticals News Today Arvinas News Today ANI Pharmaceuticals News Today Day One Biopharmaceuticals News Today Adaptive Biotechnologies News Today Arcus Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:MBX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBX Stock Alerts